|Bid||19.88 x 4000|
|Ask||20.03 x 800|
|Day's Range||19.41 - 20.48|
|52 Week Range||19.41 - 120.40|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.15|
While some market analysts point to a blue wave being value destructive to the overall market, it could boost cannabis stocks, says CFRA's Garrett Nelson.
Ask Benjamin Witte about Recess, and one of the first places he’ll send you is the company’s Instagram page.
Tilray Inc. (NASDAQ:TLRY) and HEXO Corp. (TSX:HEXO)(NYSE:HEXO) are two key stocks to keep an eye on as the cannabis space ramps up for winter.
CALGARY, Nov. 13, 2019 /CNW/ - Inner Spirit Holdings Ltd. ("Inner Spirit" or the "Company") (CSE:ISH.CN - News), a Canadian company establishing a national network of retail cannabis stores under its Spiritleaf brand, today announced plans to expand across the province of Saskatchewan with the launch of an online cannabis retail website at sk.spiritleaf.ca and the resumption of franchise sales activity directed at local entrepreneurs in the province. "We have become Canada's number one cannabis retailer by continually finding new ways to deliver the best shopping experience for our customers.
(Bloomberg) -- Tilray Inc.’s Canadian operations should be profitable sooner than the late 2020 target set for the company as a whole, according to Chief Executive Officer Brendan Kennedy.The cannabis company said Tuesday that it expects to generate overall positive earnings before interest, taxes, depreciation and amortization by the final quarter of next year. However, Kennedy said its primary Canadian business should reach the key metric sooner than that.“It’s likely that our business in Canada will be Ebitda positive before the rest of our business, just because it’s at a different stage of development,” he said Wednesday in an interview with Bloomberg TV on the sidelines of Cowen & Co.’s cannabis conference in Boston. “That business is much more mature. We’ve been operating it for six years.” Once-bullish investors have increasingly punished cannabis companies that don’t show a clear path to profitability. Tilray’s shares have fallen about 70% since the beginning of the year amid broad-based weakness across the sector. The stock was also volatile on Wednesday after the company posted a wider-than-expected Ebitda loss.Management’s optimistic forecasts have been thwarted due to a slower-than-expected retail rollout in Canada and regulatory issues in the U.S., but Kennedy said he’s confident that Tilray will meet its guidance, which assumes 800 to 1,000 stores open by the end of 2020.“We have some buffer in our targets,” he said. “That gives us a lot of confidence.”Tilray also said it has enough cash to fund its operations until it reaches positive Ebitda in late 2020, but Kennedy said it has options if it does need to raise capital.“We have about $300 million in real estate and facility assets that we own completely, so that’s clearly one option,” he said. “But at this point we haven’t moved very far down any of those paths.”To contact the reporter on this story: Kristine Owram in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Jennifer Bissell-LinskFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Tilray, Inc. (TLRY) delivered earnings and revenue surprises of -72.41% and 3.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
SAINT LAURENT, Quebec, Nov. 07, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.
The latest U.S.-China trade war news that could see the world's two largest economies roll back tariffs. Q3 earnings results from the likes of Qualcomm and Square. And why Yeti is a Zacks Rank 1 (Strong Buy) stock...
After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank 2 (Buy) or better that investors might want to consider buying right now...
Tilray and Cronos stocks are trading at 52-week lows. Here we compare various metrics between the two stocks to analyze which is a better buy at the current price.